For example, FSTL1 has been found to promote tumor inhibition in breast cancer [12] and clear-cell renal cell carcinoma [13]; however, it is a poor prognostic indicator of colorectal cancer [14], esophageal squamous cell carcinoma [15], and hepatocellular carcinoma [16]. Here, FSTL1 is linked to neoplasm.